P2Y12 inhibitors monotherapy after short course of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials including 29 089 patients.
Matteo BiancoAlessandro CareggioPaola DestefanisAlessia LucianoMaria Giulia PerrelliGiorgio QuadriRoberta RossiniGianluca CampoGiampiero VizzariFabrizio D'AscenzoMatteo AnselminoGiuseppe Biondi-ZoccaiBorja IbáñezLaura MontagnaFerdinando VarbellaEnrico CerratoPublished in: European heart journal. Cardiovascular pharmacotherapy (2022)
After a PCI with current DES, an S-DAPT strategy followed by a P2Y12i monotherapy was associated with a lower incidence of clinically relevant bleeding compared to 12 months DAPT, with no significant differences in terms of 1-year cardiovascular events.
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- cardiovascular events
- acute coronary syndrome
- coronary artery disease
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- acute myocardial infarction
- coronary artery bypass grafting
- patients undergoing
- end stage renal disease
- atrial fibrillation
- chronic kidney disease
- ejection fraction
- newly diagnosed
- combination therapy
- open label
- cardiovascular disease
- risk factors
- prognostic factors
- coronary artery bypass
- clinical trial